Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC Danielle BrazelMisako Nagasaka Leading Article Open access 13 May 2024 Pages: 297 - 301
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review Etienne BrainConnie ChenKaren A. Gelmon Systematic Review Open access 28 March 2024 Pages: 303 - 320
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study Michael MarisGilles SallesVincent Ribrag Original Research Article Open access 29 April 2024 Pages: 321 - 332
A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor Louise EvansRick WalkerDavid S. Ziegler Original Research Article Open access 28 March 2024 Pages: 333 - 342
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone James R. BerensonAndrea LimonRobert Vescio Original Research Article 20 April 2024 Pages: 343 - 357
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study Margherita RiminiGianluca MasiAndrea Casadei-Gardini Original Research Article 01 May 2024 Pages: 359 - 370
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis Michele BassoCarlo SignorelliGiampaolo Tortora Original Research Article Open access 13 April 2024 Pages: 371 - 382
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes Zucheng XieYan QinYuankai Shi Original Research Article 21 April 2024 Pages: 383 - 400
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors Taizo UchimotoShuya TsuchidaHaruhito Azuma Original Research Article 28 March 2024 Pages: 401 - 410
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients Keisuke OnoiTadaaki YamadaKoichi Takayama Original Research Article 11 March 2024 Pages: 411 - 421
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101) Naoya NishiokaHisao ImaiHiroaki Okamoto Original Research Article Open access 13 April 2024 Pages: 423 - 433
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System Sara CeccoStefano PulighedduEmanuel Raschi Original Research Article Open access 02 May 2024 Pages: 435 - 445
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer Jacob B. LearyThomas EnrightPetros Grivas Original Research Article 03 April 2024 Pages: 447 - 458
The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling Hiroyuki YamamotoHiroyuki AraiYu Sunakawa Original Research Article 13 April 2024 Pages: 459 - 471
Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma Sheridan M. Hoy Adis Drug Evaluation 09 May 2024 Pages: 473 - 480
Correction to: Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma Nicole L. FranceHannah A. Blair Correction Open access 20 March 2024 Pages: 481 - 481
